Chemaphor Inc.

Chemaphor Inc.

April 21, 2009 09:44 ET

Chemaphor Announces Option Grants

OTTAWA, CANADA--(Marketwire - April 21, 2009) - Chemaphor Inc. (TSX VENTURE:CFR), a biotechnology research and development company, today announced pursuant to the requirements of the TSX Venture Exchange, that it has granted options to purchase 58,000 common shares of Chemaphor to members of its board of directors. The stock options were granted pursuant to the terms of Chemaphor's stock option plan and are exercisable at $0.15 per share. These grants form part of a total annual remuneration package for board members. Stock option grants are subject to necessary regulatory approvals.

About Chemaphor

Chemaphor Inc. ( uses its core expertise in organic chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. Chemaphor's focus is on two proprietary products, a non-pharmaceutical product OxBC, and a lead cancer drug compound OCL-1. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information